| Preface | x |
1. | The Chemical Constituents of Cannabis sativa and the Endocannabinoid System | 1 |
2. | Pharmacology and Medicinal Chemistry of THC | 8 |
| Pharmacology of THC | 9 |
| Medicinal Chemistry | 16 |
3. | The Pharmacology and Therapeutic Potential of Cannabidiol | 32 |
| Receptor Interactions of Cannabidiol | 35 |
| Effects of CBD on Central and Peripheral Neurotransmission | 42 |
| Fate of Anandamide and Palmitoylethanolamide | 43 |
| Anxiolytic and Antipsychotic Effects | 44 |
| Anticonvulsant Effects of CBD | 46 |
| Neuroprotective Effect of CBD | 53 |
| Effects of CBD on the Production of Mediators of Inflammation and Immune Responses | 54 |
| Effects of CBD on Cancer Cell Proliferation | 59 |
| Effects of CBD on Cytochrome P450 (CYP) Isozymes | 60 |
| Effects of CBD on Membrane Fluidity and Stability | 61 |
| Other Effects of CBD | 62 |
| Interactions between CBD and [Delta superscript 9]-THC | 64 |
| Structure-Activity Relationships | 65 |
4. | Cannabinoid Receptors and Signal Transduction | 84 |
| CB[subscript 1] Receptor and Signal Transduction Pathways | 84 |
| CB[subscript 2] Receptor and Signal Transduction Pathways | 87 |
| Endothelial Anandamide Receptor: Pharmacology and Signal Transduction Pathways | 88 |
| Mechanism of Receptor-Mediated G Protein Coupling | 88 |
5. | Endocannabinoids | 98 |
| Discovery of the Endocannabinoids | 99 |
| Quantitative Analysis of Endocannabinoids in Mammals | 100 |
| Biosynthesis, Action and Inactivation of Endocannabinoids | 101 |
| Possible Physiological and Pathological Functions of Endocannabinoids in the CNS--An Overview | 113 |
| Endocannabinoids: Relax, Eat, Rest, Forget and Protect | 118 |
6. | Chemistry and Structure Activity Relationships for Tetrahydrocannabinols and Endocannabinoids | 131 |
| Endocannabinoids | 138 |
| Pyrazole Based Antagonists | 141 |
7. | Cannabinoids and Medicine: Eating Disorders, Nausea and Emesis | 147 |
| Endocannabinoids and the Physiological Regulation of Appetite and Body Weight | 147 |
| Disorders of Appetite and Body Weight | 150 |
| Obesity | 150 |
| Cachexia, Anorexia and Malnutrition in Disease | 152 |
| Nausea and Emesis | 155 |
8. | Cannabinoids and Medicine II: The Role of Cannabinoids in Multiple Sclerosis and Neuronal Damage | 161 |
| Multiple Sclerosis | 162 |
| Head Injury and Stroke | 167 |
| Glaucoma | 169 |
| Parkinson's Disease | 170 |
| Huntington's Disease | 171 |
| Motor Neuron Diseases | 172 |
| Alzheimer's Disease | 173 |
9. | Endocannabinoids and Related Fatty Acid Derivatives in Pain Modulation: Behavioral, Neurophysiological and Neuroanatomical perspectives on Cannabinoid Antinociception | 181 |
| Functional Significance of a Cannabinoid Transmitter System | 181 |
| Subtypes of Cannabinoid Receptors | 182 |
| Endocannabinoids | 182 |
| Cannabinoid Receptor Pharmacology | 183 |
| Antinociceptive Effects of Cannabinoids | 183 |
| Cannabinoid-Induced Suppression of Nociceptive Transmission | 183 |
| Spinal and Peripheral Cannabinoid Antinociceptive Mechanisms | 184 |
| Evidence for Endocannabinoid Modulation of Nociception at the Supraspinal Level | 187 |
| Role of Other Endocannabinoids and Related Fatty Acid Derivatives | 189 |
| Localization of Cannabinoid Receptors and mRNA | 190 |
| Cannabinoid Receptor Distribution on Central Terminals of Primary Afferents | 193 |
10. | Endocannabinoids and Alcohol Drinking Behavior | 205 |
| Endocannabinoids and Brain Reward Mechanisms | 205 |
| Endocannabinoids As Regulators of Alcohol Preference | 206 |
| Age-Dependence of Alcohol Preference and Endocannabinoid Signaling in Mice | 207 |
| Endocannabinoids and Alcohol-Withdrawal | 209 |
| A New Hypothesis | 209 |
| Index | 213 |